Ogeda is a clinical-stage drug discovery company that invents and develops small molecule drugs targeting G-Protein Coupled Receptors. Ogeda leads the development of NK3 antagonists for the treatment of hormone-dependent pathologies in Women's Health. Its lead product, fezolinetant has shown positive results in a Phase IIa proof-of-concept clinical study in Menopausal Hot Flashes, and studies in PolyCystic Ovary Syndrome and Uterine Fibroids are in progress. Ogeda's portfolio further includes several pre-clinical drug discovery programs in endocrine, CNS and/or inflammatory disorders. Ogeda was acquired by Astellas Pharma on April 2, 2017